Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
The key events that shaped the Medtech Insight Top 100 by sales in 2019
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
You may also be interested in...
Outgoing US FDA chief Stephen Hahn has signaled that he’ll seek a posting in public health, where he can increase equity and help in the fight against COVID-19.
After a year like no other for the global medtech industry, 2021 will present a different set of market challenges for device and diagnostic companies.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.